title: A real all-comers randomized trial comparing Xience Prime and Promus Element stents.
abstract: BACKGROUND
  The cobalt chromium everolimus-eluting stent (CoCr-EES) has shown the best safety and efficacy profile in the trials conducted so far. Recently, a new EES with a platinum-based platform (PtCr-EES) has been introduced in the market. There is only one study comparing both stents, but with important exclusion criteria.
  
  
  OBJECTIVE
  We sought to evaluate clinical outcomes with the PtCr-EES compared with the CoCr-EES in an all-comers population. We have conducted a randomized all-comers study aimed to compare these stents in a real-practice scenario.
  
  
  METHODS
  A total of 300 patients undergoing revascularization and suitable for long-term dual-antiplatelet therapy were randomized 1:1 to CoCr-EES or PtCr-EES. No exclusion criteria based on clinical presentation or lesion characteristics were applied.
  
  
  RESULTS
  The clinical and angiographic characteristics were well balanced in both groups without significant differences. At 18 months, the survival free from death and infarction was 93.9% for CoCr-EES and 91.3% for PtCr-EES (P=.3), the survival free from revascularization was 95.2% vs 94.5% (P=.6) and the survival free from death, infarction, and revascularization was 90.6% vs 88%, respectively (P=.4). The incidence of definite or probable thrombosis was 1.3% for CoCr-EES and 0.66% for PtCr-EES (P=.9). No cases of longitudinal stent compression were observed.
  
  
  CONCLUSIONS
  The results of this all-comers trial do not show significant differences between CoCr-EES and PtCr-EES. However, the sample size is not powered to exclude potential differences between stents.
authors.affiliation: Unidad de Hemodinámica y Cardiología Intervencionista, Hospital Universitario Marques de Valdecilla, 39012 Santander, Spain. he1thj@humv.es
authors.forename: Jose M
authors.initials: JM
authors.lastname: De la Torre Hernandez
authors.forename: Tamara
authors.initials: T
authors.lastname: Garcia Camarero
authors.forename: Piedad
authors.initials: P
authors.lastname: Lerena
authors.forename: Dae-Hyun
authors.initials: DH
authors.lastname: Lee
authors.forename: Fermin
authors.initials: F
authors.lastname: Sainz Laso
authors.forename: Gonzalo Martin
authors.initials: GM
authors.lastname: Gorria
authors.forename: Javier
authors.initials: J
authors.lastname: Zueco
mesh_terms: D000368:Aged; D060050:Angina, Stable / Q000628:therapy; D000789:Angina, Unstable / Q000628:therapy; D002858:Chromium Alloys; D023903:Coronary Restenosis / Q000453:epidemiology; D054855:Drug-Eluting Stents / Q000009:adverse effects; D004868:Equipment Failure; D000068338:Everolimus; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods; D010984:Platinum; D020123:Sirolimus / Q000031:analogs & derivatives*; D013927:Thrombosis / Q000453:epidemiology; D016896:Treatment Outcome
chemical_list: D002858:Chromium Alloys; D010984:Platinum; D000068338:Everolimus; D020123:Sirolimus